IM Therapeutics is developing personalized medicines for autoimmune diseases by building oral drug therapies against human leukocyte antigen (HLA) variants that confer high risk of disease. The Company platform screens millions of compounds for optimal docking within HLA proteins together with rational drug design and bioassays to develop targeted therapeutic candidates. Its lead drug, IMT-002, is directed at HLA DQ8 activity for treatment of type 1 diabetes. The Company is building a broad pipeline of drugs against HLA targets in autoimmune disorders including celiac disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/09/19 | $10,000,000 | Series A |
Colorado University Healthcare Innovation Fund JDRF T1D Fund  Morningside Group | undisclosed |
